News Hub | News Direct

American Medical Association Grants Cardio Diagnostics (NASDAQ: CDIO) Reimbursement Codes For AI-Powered Coronary Heart Disease Tests

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics’ AI-driven coronary heart disease (CHD) tests have taken another promising step in their evolution. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, has been assigned two dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA); 0440U for the company’s AI-driven CHD detection test, PrecisionCHD, and 0439U for the company’s AI-driven CHD event (heart attack) risk assessment test, Epi+Gen CHD. Assigned by the American Medical Association (AMA), these two new CPT PLA codes – effective April 1, 2024 – mark a significant step toward payer billing and payment for the company’s groundbreaking tests. The designation will facilitate the broader adoption of PrecisionCHD, an integrated genetic-epigenetic clinical blood test to aid in the diagnosis of CHD, and Epi+Gen CHD for evaluating the likelihood of a patient experiencing a CHD event – mainly a heart attack – within the next three years. Treating A Growing Problem Every year, about 805,000 people in the United States have a heart attack, meaning someone experiences a heart attack every 40 seconds. Heart disease is the leading cause of death for both men and women. According to the CDC, in 2021, heart disease was responsible for the deaths of more than 695,000 Americans – representing one in every five deaths. The most common type of heart disease and the major cause of heart attacks, CHD was responsible for over 375,000 deaths in 2021, and CHD-associated medical costs are estimated to be about $239.9 billion according to an estimate by the CDC in its heart disease fact sheet. Combating this growing problem, Cardio Diagnostics reports that PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD. The PrecisionCHD test has the ability to aid in the diagnosis of CHD and provide personalized insights to help prevent a heart attack and improve outcomes. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD. Identifying patients with CHD and intervening before a heart attack occurs are essential to reducing the unprecedented economic and health burden associated with CHD. Until now, the lack of readily accessible and cost-effective diagnostic solutions for CHD has posed a challenge leading to delayed diagnosis and care, particularly among underserved and minority populations. Increasing access, the PrecisionCHD test only requires a simple blood draw and can be deployed remotely, allowing it to be scaled without the need for specialized infrastructure. This enables more timely intervention and management. “Receiving a dedicated CPT PLA code for PrecisionCHD is a critical milestone in our commercialization strategy,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “With PrecisionCHD, we believe that expanding equitable access to CHD diagnostics and improving patient health outcomes while reducing healthcare expenditure is possible.” While PrecisionCHD aids in diagnosing CHD, Cardio Diagnostics’ Epi+Gen CHD evaluates an individual’s genetic and epigenetics to predict their risk for a heart attack or sudden cardiac death associated with CHD. By leveraging the powerful personalized insights driven by the company’s groundbreaking epigenetic-genetic technology, the company can provide patient-specific epigenetic and genetic drivers of CHD to help guide preventive care that could potentially save lives. In peer-reviewed studies, Epi+Gen CHD was more cost-effective and sensitive for assessing heart attack risk when compared to standard lipid-based risk calculators. Specifically, in a validation study conducted with Intermountain Healthcare, Epi+Gen CHD was shown to be, on average, about twice as sensitive in detecting risk for a CHD event in women than lipid-based calculators. For employers, the financial burden of heart attacks includes direct costs related to diagnosing, managing and treating heart disease. Indirect costs include lost productivity due to employee absenteeism and short-term disability, which can indirectly cost employers about $1,119 per month for upwards of three years. Cardio Diagnostics’ technology can help employers better inform their benefits offerings by combining the ability to offer employees the advanced Epi+Gen CHD heart attack risk test with aggregated risk data. Cardio Diagnostics’ Employer Risk Intelligence platform provides employers and brokers with the first-of-its-kind cardiovascular employee population health intelligence backed by a clinical test and layered insights, completed in a compliant manner. As such, Epi+Gen CHD’s new reimbursement code could mean greater access to technology that enables a healthier workforce and significant savings in healthcare costs related to heart disease. “Cardio Diagnostics is committed to driving widespread adoption of our solutions, and obtaining a reimbursement code for Epi+Gen CHD is a critical milestone in our commercialization strategy and for gaining reimbursement from federal and private payers,” Dogan said. Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks. The company is committed to making heart disease risk assessment, detection and management more accessible, and it believes personalized and precise diagnostics are key to winning the fight against the leading cause of death in the United States. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

January 30, 2024 08:20 AM Eastern Standard Time

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002

Benzinga

By Jeremy Golden, Benzinga Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the second and third leading causes of cancer death, respectively. Pancreatic and colorectal cancers are often Kirsten rat sarcoma (KRAS) mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. KRAS mutations are among the most prevalent human cancers. For these cancers, caused by a mutation of the KRAS gene, clinical-stage biotechnology company Elicio Therapeutics Inc. (NASDAQ: ELTX) is developing a pipeline of novel immunotherapies for treatment. Founded in 2011, Elicio Therapeutics has developed an innovative pipeline of cancer immunotherapies addressing critical unmet needs. Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008. Elicio’s lead clinical program, ELI-002, is a structurally novel investigational AMP therapeutic immunotherapy targeting mutant KRAS-driven cancers. It was designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors. ELI-002 2P has been studied in a phase 1 dose-escalation study in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy. After early findings from AMPLIFY-201 were released, ELI-002 was the subject of a publication in Nature Medicine. The paper — “ Lymph Node Targeted, mKRAS-specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer: The phase 1 AMPLIFY-201 Trial ” — details expanded and updated results that point to the power of Elicio Therapeutics’ use of precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against solid tumors. Originally presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2023 AACR Special Conference on Pancreatic Cancer, the data detailed in the publication is as of September 6, 2023. It is based on 25 patients with solid tumors (20 pancreatic, 5 colorectal) who were positive for minimal residual mKRAS disease after locoregional treatment. “When tumor DNA or protein persists or recurs after treatment, patients with pancreatic and colorectal cancers are unfortunately not left with many options and are often incurable,” said study author Shubham Pant, M.D., Associate Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. “These are promising early findings from the AMPLIFY-201 study with follow up ongoing. Most patients reduced their tumor biomarkers with some having complete clearance following treatment with ELI-002.” “The lymph node-targeted cancer vaccine candidate induced direct ex vivo mKRAS-specific T cell responses in 84% of patients, with 59% of patients demonstrating a response with two key types of T cells: helper cells and killer cells,” according to Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer. “Past studies have not produced this large a fraction of patient response, this high a magnitude of a response or the expansion of both key populations of T cells,” he said. “Importantly, these T cell responses were specific to tumor-driver mutant KRAS neoantigens, correlated with reduced risk of relapse and we saw a pool of memory T cells form that we believe hold promise to confer long-term protection,” Haqq said. “We look forward to progressing ELI-002 into a randomized phase 2 trial as a monotherapy for patients with PDAC.” ELI-002 7P is currently being studied in AMPLIFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations, thereby increasing the potential patient population for ELI-002 and possibly reducing the chance of bypass resistance mechanisms. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 30, 2024 08:10 AM Eastern Standard Time

InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need

Benzinga

By Meg Flippin, Benzinga Cannabinoids are having a moment in treating everything from Alzheimer’s to ocular diseases and InMed Pharmaceuticals Inc. (NASDAQ: INM) seems to be at the center of it all. The leader in cannabinoids and cannabinoid analogs pharmaceutical research, development, manufacturing and commercialization hit key milestones in advancing its cannabinoids-based treatments for Alzheimer’s disease, age-related macular degeneration (AMD) and epidermolysis bullosa in 2023 with more inroads to come in 2024. Take Alzehimer’s for starters. The disease is a big and growing problem afflicting about 6.7 million people 65 and older in the U.S. By 2060 it’s projected that 14 million people in the U.S. will suffer from the degenerative neurological disease. Treatments exist to address the symptoms related to memory and cognitive function and in some instances slow the rate of cognitive decline, but none have been able to reverse disease effects. Making An Impact InMed hopes to change that with INM-901, a rare cannabinoid analog the company says has the potential to target several biological pathways associated with Alzheimer’s. Previous industry research has shown cannabinoids hold promise in not only slowing the progress of Alzheimer’s but potentially reversing its effects thanks to their neuroprotective and regenerative properties. InMed’s data from preclinical i n vivo studies released last year showed INM-901 improved cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. INM-901 also displayed neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study. To further evaluate INM-901 in 2024, InMed has initiated longer-term, six-month preclinical studies in behavior models. At the same time, the company is gearing up to launch more advanced preclinical studies, encompassing drug distribution, metabolism, active pharmaceutical ingredients and drug product formulation/manufacturing. Cannabinoids Can Protect Eyes Another big disease InMed is going after is age-related macular degeneration or AMD, which is a common cause of vision loss and potential blindness in people over 50. Based on 2019 estimates, AMD afflicts 19.8 million people or 12.6% of Americans 40 and up. Globally it affects 35% of people 74 and older. As it stands, there is no cure for AMD although treatment can prevent or slow the progression of the disease. Left unchecked patients may lose central field vision in the affected eye within 24 months of disease onset. INM-089, InMed’s ocular program for AMD launched in November is showing promise in changing that. Preclinical studies showed the potential for the drug to preserve retinal function, proactively protect the retinal cells that are responsible for vision and enhance the thickness of the outer nuclear layer of the retina where photoreceptors are situated, InMed said. Coming off those positive results, InMed is engaged in advanced preclinical studies and drug product formulation work, and it plans to launch Investigational New Drug studies in mid-2024. The goal is to file an Investigational New Drug application with regulatory authorities in the first half of 2025. “As we embark on 2024, we are placing increased emphasis on proprietary small molecule drug development candidates in our pharmaceutical pipeline with two exciting new programs addressing critical unmet medical needs,” said InMed CEO Eric A. Adams. “Our focus on developing proprietary cannabinoid analogs over the past two years has started to pay dividends, evident in their utilization in these two new preclinical programs.” Dermatology Program Additionally, last year, the company successfully completed a phase 2 clinical trial in the treatment of epidermolysis bullosa or EB, a rare genetic skin disease marked by fragile skin that can lead to extensive blistering and wounding. Data from a phase 2 clinical trial of INM-755 showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone, warranting further development. InMed thinks INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments and is currently seeking partnerships for continued development. Supplier To All In addition to developing its own treatments, InMed is a key supplier of rare cannabinoids as ingredients to the health and wellness market. The company’s BayMedica unit focuses on being a low-cost/high-quality manufacturer of certain non-psychoactive rare cannabinoids and an ingredients supplier to brands within the health and wellness industry. In 2023, the company said the unit experienced “significant” year-over-year revenue growth, and it is making moves to capitalize on revenue-generating opportunities in 2024. To that end, BayMedica is embracing a distributor model to expand coverage across the U.S. InMed is betting consumer brands will use more rare cannabinoid ingredients in 2024 – and InMed will be ready to provide them. “BayMedica continues to drive robust year-over-year revenue growth. The foreseeable future looks promising for the health and wellness segment as demand for minor cannabinoid ingredients continues to gain momentum,” said Adams. Cannabinoids hold promise to treat and potentially cure several diseases. InMed seems to be at the forefront of these groundbreaking advances. If 2023 is any indication, investors may want to watch for more milestones out of InMed this year and beyond. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 26, 2024 08:40 AM Eastern Standard Time

The best generative AI solutions of 2024

AIport

January 25, 2024 — Ever since ChatGPT burst onto the scene in the fall of 2022, generative AI (GenAI) solutions have continued to disrupt industries with their surprising and never-before-seen features. Many of the generative AI solutions we hear about today are based on large language models (LLM), which allow them to successfully communicate with end users. Every such model has to be pre-trained on vast amounts of data and then fine-tuned using a variety of different methods. As we’re approaching the end of January, let’s look at the list of the most noteworthy of these models and explore the generative AI solutions they power. Compiled by the AIport newsletter team, this list is by no means exhaustive, but it is a review of what we believe are the LLM-based generative AI solutions and tools that are likely to make headlines this year. GPT (OpenAI and Microsoft) Expectedly, the first LLM on our list with some of the highest expectations this year is at the core of ChatGPT from OpenAI. GPT wasn’t the first LLM out there (there had been others like BERT ), but it was certainly the first one that resulted in a market-ready GenAI product. The original GPT model (Generative Pretrained Transformers) had 170 billion parameters, while the latest version, GPT-4, boasts over 1.75 trillion. The model’s applications are far and wide, being the basis not only for ChatGPT, but also Microsoft’s Bing Chat, which is now part of the Copilot infrastructure. While ChatGPT remains arguably the most impressive text-producing GenAI tool, Bing Chat (unlike ChatGPT) has internet access, making it ideal for web browsing. In addition, the same core GPT model is being utilized by other entities — from Panasonic Connect in Japan, OCBC Bank’s ChatGPT in Singapore, and KPMG’s KaiChat in Germany to the UK government’s upcoming GOV.UK chat. Notably, GPT is also a vital part of OpenAI’s DALL-E suite — a solution that generates images based on descriptions from text. PaLM and Gemini (Google) The next one on our list is Google’s PaLM (Pathways Language Model). The model, boasting 540 billion parameters, was first successfully tested in the spring of 2022. A year later, PaLM 2 was announced and subsequently integrated into Bard — Google’s GenAI chatbot — becoming available to test users around the world. Bard is considered among the finest solutions for productivity, having internet access like Bing Chat, but being less about navigating the web and more about answering burning questions. Bard was seriously bolstered at the end of last year with Google’s highly anticipated launch of the multimodal LLM, Gemini, which had been trained on images and audio/video files, not just text. The jury is still out on how far this update will take Bard, but the expectations are very high indeed. LLaMA (Meta, Microsoft, and Hugging Face) LLaMA (Large Language Model Meta AI) from Meta was released in February last year. However, the 65-billion-parameter model was leaked online as a downloadable torrent only a week later. While the model did not lead to any ChatGPT-like products at Meta, another AI company — Hugging Face — picked it up and released Hugging Chat. Offering internet access, this GenAI solution has been praised as “the first open source alternative to ChatGPT” with a snarky sense of humor. Not to be outdone, Meta partnered with Microsoft to produce LLaMA 2 in July of last year. Following that, the company announced a beta release of Meta AI at the end of September — a GenAI chatbot, currently available in the US, that can “provide real-time information and generate photorealistic images” from text prompts. This solution is expected to reach Meta users across the rest of the globe later in the year. Claude (Anthropic) Our next LLM is made by Anthropic, and it’s named Claude. Founded in 2021, the company along with its language model may be a less familiar name to most non-geeks. But this is likely to change in 2024. That’s the case not only because the latest version of the namesake GenAI chatbot released last year can now process long PDF files of up to 75,000 words, taking moments to summarize entire books. But also because this has already caught the attention of both Google and Amazon who are keen to invest $2 and $4 billion respectively. While Claude doesn’t offer internet access, its processing power, namely input character memory, outpowers every competitor by a wide margin, including ChatGPT. And the company is said to be working on yet more handy features as we speak. HyperCLOVA X (Naver) HyperCLOVA X is both the LLM and the namesake GenAI chatbot released by the South Korean search engine giant, Naver, last August. Boasting over 200 billion parameters, the LLM is being used mainly for AI-assisted web browsing, much like Bing Chat. While HyperCLOVA X doesn’t speak English, the chatbot’s proficiency in Korean is impressive, having learned 6,500 more Korean words than ChatGPT. In addition to answering user queries, HyperCLOVA X has been designed to offer AI assistance to businesses across numerous sectors — from finance to gaming. Naver is also presently working to make HyperCLOVA X multimodal, following in the footsteps of Google’s Gemini, so another big international headline is likely on the way. Pangu (Huawei) Last spring, Huawei, one of the global tech leaders, unveiled Pangu — an LLM with 1.085 trillion parameters in over 40 natural and programming languages. This LLM now powers the Chinese company’s GenAI assistant called Celia, which resides within Huawei’s HarmonyOS 4 operating system. Supposedly, Celia has already outperformed both Siri and Google Assistant as a phone-based virtual assistant in terms of prompt execution accuracy, such as finding specific photos and documents stored on a device. And as more Huawei smartphones are being churned out, Celia is expected to reach more global users this year with further refinements to the Pangu model. In addition, Pangu is available through Huawei Cloud for commercial use. According to a statement from the company’s leadership, the newest Pangu 3.0 utilizes hierarchical architecture, allowing it to be quickly fine-tuned for a wide range of downstream applications (including Huawei’s autonomous vehicle solutions ), which we’ll surely see more of in 2024. MiLM-6B (Xiaomi) Next up is another Chinese company, Xiaomi — one of the largest phone manufacturers in the world. The company made an entry into the LLM race last summer with its MiLM-6B, a lightweight model created for mobile devices. Boasting 6.4 billion parameters, MiLM-6B has reportedly outperformed rivals in its category and achieved notable scores from evaluation platforms like C-Eval and CMMLU. Xiaomi’s leadership has been vocal for some time about integrating LLMs into its smartphones. It appears that the company’s virtual assistant, Xiao AI, has now finally become a fully fledged GenAI chatbot, generating over 11 words per second. By this metric, despite operating locally on the phone, Xiao AI has matched the performance of some LLMs running on cloud computing services. It’ll be interesting to see whether Xiao AI gets assimilated into the company’s other products, as the rumors suggest, including the recently announced Xiaomi SU7, an autonomous-enabled electric sedan. YandexGPT (Yandex) The final entry on our list is an LLM named YandexGPT from the Russian search engine Yandex. The namesake GenAI solution with 100 billion parameters was beta-released in May last year. The more recent release of YandexGPT2 has demonstrated a 65% improvement in response quality, with a 1.5-fold increase in training data. Interestingly, this GenAI solution was tested and scored enough points to enter a Russian university. YandexGPT was also integrated into Yandex’s flagship virtual assistant named Alice, as well as the company’s smart speakers. Furthermore, the LLM has allowed the company’s e-shoppers to view summarized customer reviews in one place. With YandexGPT at the core, the company now also offers visual GenAI solutions, YandexART and Shedevrum, that can generate images from text, much like Open AI’s DALL-E. Currently, the LLM is also being merged with Yandex Search to offer the end user something similar to Bing Chat and HyperCLOVA X. It’s likely that we’ll see a new announcement pertaining to this development later in the year. New kids on the block Apart from the above entries on our list, several brand new LLMs along with their GenAI solutions are expected to arrive any day from other big players. Among them are Samsung from South Korea, Tencent from China, as well as Amazon and Apple. In fact, Apple already has an internal AI chatbot for employees, but its much-talked-about AppleGPT based on the company’s LLM, Ajax, is said to be around the corner. Amazon began to offer a service for building AI chatbots called Lex a while ago, but more notably, the company recently announced its upcoming GenAI solution tailored for commercial use. Japan doesn’t intend to be left behind either — at least three major LLM initiatives are currently being played out. Among them is a joint project between Fujitsu, RIKEN, Tokyo Tech, and Tohoku University who are developing a series of LLMs using one of the world’s most powerful supercomputers, Fugaku. In addition, both NTT and SoftBank are reportedly in the final stages of developing their “homegrown” LLMs. While much remains unclear and covered in mist (or is it gray goo 😉), one thing is certain — 2024 is going to be the most AI-intense year we have seen yet! If you enjoyed this listicle, visit AIport for more exclusive insights into the latest tech trends, with a focus on the global ML landscape. All trademarks mentioned are the property of their respective owners. Contact Details NettResults PR Nick Leighton +1 949-478-5880 nick.leighton@nettresultsllc.com Company Website https://aiport.substack.com/

January 25, 2024 09:53 AM Pacific Standard Time

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

Kadimastem

Ness Ziona, Israel, January 25 th 2024, Kadimastem (TASE: KDST), a well-known biotech company in the field of cellular therapy, which is in the clinical development stages of innovative products for the treatment of ALS and diabetes, announced today the publication of the peer-reviewed prestigious journal of Clinical Toxicology. The article describes the development and safety of the new off the shelf cryopreserved AstroRx cell product in toxicity studies. Intrathecal injection of both low dose of DMSO (vehicle control) used for cryopreservation of human astrocytes and the cryopreserved AstroRx® cell product demonstrated high safety profile in mice. Link to the article. The article details the important milestone achieved by the company in the development of cryopreserved AstroRx® off the shelf cell product that will be thawed and injected near the patient's bedside. The development of a cryopreserved cell therapy product would allow the completion of more accurate and longer sterility testing, the completion of potency results, simplify the process of manufacturing scaling, enable long term storage and transport and facilitate timing of therapy delivery to the patient. The Cryopreserved product will help secure the clinical objectives of the upcoming IND approved phase IIa clinical trial in 30 ALS patients. Kadimastem's AstroRx® cell product is an allogeneic cell-based product composed of healthy and functional human astrocytes derived from embryonic stem cells. AstroRx® acts through multiple mechanisms of action that increase the survival of neurons, such as removal of toxic excessive glutamate, reduce oxidative stress, secrete various neuroprotective factors, and act as an immunomodulator. Dr. Michal Izrael, Kadimastem's VP R&D says: “The new formulation of cryopreserved of the shelf AstroRx® cell product (“thaw and inject”) is of great importance for product commercialization as well as to the success of our upcoming phase II clinical study, as it permits coordination of cell administration with patient care and completion of safety and quality control testing before cell administration.” Asaf Shiloni, Kadimastem’s CEO says: “We would like to thank Kadimastem's dedicated team for achieving this significant milestone. We are very excited to move towards our next Phase IIa clinical study approved by the FDA, with the new off-the-shelf AstroRx® cell product which will be tested using repeated intrathecal injections of AstroRx® in ALS patients.” About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook Contact Details Asaf Shiloni CEO s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

January 25, 2024 08:24 AM Eastern Standard Time

Image

Centre for Neuro Skills Announces New General Counsel

Centre for Neuro Skills

Bakersfield, Calif. (Jan. 24, 2024) Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, today announced the appointment of Jamie Mason, J.D., as general counsel. “Jamie has extensive in-house counsel experience and a strong background in healthcare,” says Nicholas Ashley, chief governance officer of Centre for Neuro Skills. “She is a fast learner and quickly integrated herself with the team. We are fortunate to have her in the company to keep us moving forward.” Mason joined CNS as assistant general counsel in March 2023. As general counsel, she will oversee all aspects of the organization’s legal, risk management and regulatory performance efforts. Mason will provide oversight across all seven CNS clinics throughout California and Texas. Mason received her Juris Doctor degree from Southwestern Law School and has more than 10 years of experience as a trial attorney, primarily representing hospitals, medical groups, physicians and attorneys. The CNS Bakersfield clinic is the company’s flagship location, established in 1980. CNS has two other clinics across California in Los Angeles and San Francisco, as well as four Texas clinics in Dallas, Fort Worth, Houston and Austin. Through inpatient, outpatient, day treatment and residential rehabilitation programs, CNS’ facilities provide tailored neurorehabilitation therapy to patients. “Centre for Neuro Skills is not only an industry leader in post-acute neurorehabilitation services but also a pioneer in healthcare with unmatched passion, innovation and growth,” said Mason. “It is an honor and privilege to serve as general counsel for CNS, and contribute to making a positive impact on our patients’ lives.” *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

January 24, 2024 07:00 AM Pacific Standard Time

Image

Research Collaboration Validates MyAnIML’s AI-Powered, Facial Recognition Cattle Predictive Health Platform

MyAnIML

A collaborative study between animal agtech startup MyAnIML and the United States Department of Agriculture (USDA) successfully corroborated the technology's predictive ability to proactively manage devastating disease outbreaks in cattle production. MyAnIML used proprietary facial recognition and deep learning technology to accurately predict Infectious Bovine Keratoconjunctivitis (IBK), or bovine pinkeye, 99.4% of the time and several days before veterinarians were able to detect symptoms, according to published study results. USDA Agricultural Research Service scientists Mike Clawson and Larry Kuehn, who have researched IBK for years at the U.S. Meat Animal Research Center, shared their expertise on the project. “Early detection of disease is critical to healthy herd management – giving producers the chance to separate sick animals, control spread and judiciously use antibiotics before a large outbreak occurs,” said Mike Clawson, an USDA Agricultural Research Service molecular biologist and project researcher. “The results of the MyAnIML study demonstrate how far and how impactful AI-powered technology can be toward ensuring a safe, resilient and sustainable U.S. food supply chain.” The MyAnIML and USDA study included 870 beef cattle located on three different Kansas ranches during the summers of 2021 and 2022. Bovine pinkeye is highly contagious and the most common ocular disease of cattle globally, costing U.S. producers alone an estimated $150 million annually in lost performance and treatment costs. There are no effective vaccines for IBK, forcing producers to treat infected animals with antibiotics, thereby elevating the risk of developing antibiotic-resistance bacteria strains that threaten human health. Building off this collaboration, MyAnIML and USDA are applying the technology next to predict Bovine Respiratory Disease (BRD). As the single most economically impactful cattle disease, BRD costs the U.S. feedlot industry potentially more than $900 million annually, according to the American Society of Animal Science. “Building off our AI platform’s ability to distinguish between ‘healthy’ and ‘sick’ cattle two to three days before symptoms were diagnosed, the next step is expanding MyAnIML’s repertoire of diseases and health events to offer producers new tools to ensure a safe food supply,” said Shekhar Gupta, MyAnIML CEO and founder. MyAnIML’s patent-pending technology platform uses AI, facial recognition and inexpensive GoPro cameras to automatically capture and analyze subtle changes in a cow’s muzzle. Like a human fingerprint, each cattle muzzle is unique, and can be used to track specific cows. However, MyAnIML, is the first to use muzzle dermatoglyphics to not only identify cows, but as a health predictor of diseases such as BRD, IBK, foot root and uterine infections, proving that subtle changes in the bumps and ridges on a cow muzzle are a precursor of a health event. MyAnIML’s trial partners have also successfully used the technology to monitor the health status of cows going into estrus, early stages of labor and even subtle health stressors, like the need for more nutrition while nursing calves. "The muzzle is an incredible mirror into cattle health and well-being. Humans just didn’t have the ability to ‘see’ what the muzzle was telling us without the help of MyAnIML’s advanced AI and facial recognition technology,” Gupta said. Since its founding in 2021, MyAniML has: Developed a proprietary dataset of 3000 muzzle images of beef cattle, the first cattle facial and muzzle image library for health management. Partnered in trial projects with multiple Midwest cattle production facilities. Released an inexpensive Bluetooth-enabled “smart” ear tag and app that helps large-scale commercial feedlots and stockyards quickly locate potentially sick animals identified by the MyAnIML predictive platform. Signed a partnership agreement with DairyFi an India-based startup, in January. With 308 million cows, India has the largest cattle herd in the world, but suffers from lack of adequate cattle health services, greatly reducing the economic and productivity potential of India’s cattle industry. With positive results from the collaboration, large-scale trials, veterinarian feedback and ongoing product development, MyAnIML is getting ready for broad-scale commercialization. The company received angel investment funding in 2021 and is currently in the process of a seed funding investment round to expand its technology in cattle, as well as to include other livestock and companion animals. About MyAnIML MyAnIML invented and is commercializing the first-of-its-kind platform for early disease prediction in cattle using facial recognition technology focused on a cow’s muzzle. The initial discovery is the product of intense curiosity and a sense of purpose by the founder, a leading expert in generative AI and emerging uses of web-based blockchain technology. MyAnIML’s mission is to help ensure the health and well-being of cattle while ensuring an affordable and safe food supply. For more information www.myaniml.com. Contact Details AgTech PR Georgie Smith +1 360-929-0244 georgie@agtechpr.com Company Website https://www.myaniml.com

January 23, 2024 08:00 AM Central Standard Time

Image

RZ Publish Nooro Foot Massager Reviews: Why It Is Used In The United States?

Spark Metro PR

Are you tired of living with constant burning and tingling in your feet due to neuropathy? Frustrated with painkillers that merely numb the discomfort without addressing the root cause? If so, you're not alone. Many have experienced the struggle of seeking relief from neuropathic pain, only to find temporary solutions. However, you are lucky to have come across this review because it is a comprehensive report about a breakthrough device popularly known as Nooro Foot Massager that goes beyond masking the symptoms, offering a chance to reverse nerve damage and regain a life free from persistent foot pain. In a world where traditional remedies may involve uncomfortable movements, Dr. Jeremy Campbell, in collaboration with the innovative med tech startup Nooro, introduces Nooro Foot Massager as a simple at-home solution for foot pain powered by Neuromuscular Electrical Stimulation (NMES) technology. This is where the story takes a turn towards hope and healing. Are you ready to break free from neuropathic pain and experience the relief you've been longing for? The Nooro Foot Massager might just be your key to a new lease on life. What Is Nooro Foot Massager? Nooro Foot Massager is a revolutionary at-home solution developed through the collaboration of Dr. Jeremy Campbell and the innovative med tech startup, Nooro. Designed to address neuropathic foot pain, Nooro Foot Massager device employs NeuroMuscular Electrical Stimulation (NMES) technology to offer relief in the comfort of your home. Specifically named the Nooro Foot Massager, this device stands out by delivering a unique combination of targeted electric impulses deep into the tissues of your feet and legs. The primary goal? To kickstart blood circulation, a crucial factor in providing the oxygen necessary for nerve recovery. By enhancing blood flow to your feet, the Nooro Foot Massager becomes a catalyst for nerve repair and healing. This breakthrough approach holds the promise of reducing the burning pain, tingling, and numbness associated with neuropathy. The ultimate result? A chance to reclaim the activities you love, free from the constant foot pain and swelling that may have confined you. This user-friendly device opens doors to a life where neuropathic pain no longer dictates your daily experiences, offering a pathway to comfort and mobility. In essence, the Nooro Foot Massager is more than just a device – it's a transformative tool designed to empower you on your journey to relief from neuropathic foot pain. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Features (Nooro Foot Massager Reviews USA) EMS Technology: The Nooro Foot Massager employs advanced NeuroMuscular Electrical Stimulation (EMS) technology. This technology facilitates the penetration of steady electric impulses deep into the tissues of the feet and legs, aiming to relieve muscle tension, increase blood circulation, and strengthen weakened muscles. Cordless Convenience: The Nooro EMS Foot Massager offers a cordless design, eliminating the hassle of dealing with tangled cords during use. Charging is simple using the provided electricity plug and cable, ensuring a convenient and clutter-free experience. Optional Preparatory Step: While optional, the recommendation to wash your feet and remove excess skin before using the massager adds a thoughtful touch. This preparatory step enhances the overall effectiveness of the massage treatment, promoting a more thorough and satisfying experience. Versatile Massage Modes: The device features a variety of different modes, providing users with options to cater to their specific needs. Whether you're looking to relax after a long day or target particular muscle groups causing discomfort, the Nooro Foot Massager's versatility ensures a customized and enjoyable experience. Adjustable Intensity Levels: Tailoring the massage experience to individual preferences, the massager offers a mind-bending number of speed settings. This wide range allows users to find the perfect intensity level, ensuring that the massage is both effective and comfortable for various muscle groups. User-Friendly Operation: The massager's simplicity is a standout feature. With easy-to-follow steps—place your feet on the foot pad, select the mode, and adjust intensity—you can initiate the massage effortlessly. The user-friendly design ensures that anyone can enjoy the benefits without a steep learning curve. Effective Neuropathy Relief: The Nooro Foot Massager is specifically designed to address neuropathic foot pain. By enhancing blood circulation, relieving muscle tension, and providing a targeted massage experience, the device aims to alleviate burning pain, tingling, and numbness. Users can experience liberation from the challenges of neuropathy, promoting overall foot health and well-being. Benefits Of Nooro Foot Massager Pain Alleviation: A primary benefit of the Nooro Foot Massager is its ability to ease neuropathic foot pain. By employing advanced EMS technology, the massager delivers targeted electric impulses to alleviate burning sensations and discomfort associated with neuropathy. Users may experience significant relief from persistent foot pain. Tingling Relief: This innovative EMS massager targets nerve-related tingling sensations by enhancing blood circulation. Through its unique combination of electric impulses, the Nooro Foot Massager aims to improve oxygen supply to peripheral nerves, reducing tingling and promoting a sense of comfort. Numbness Reduction: For individuals experiencing numbness due to neuropathy, the Nooro Foot Massager offers hope. By increasing blood flow to the feet and facilitating nerve repair, the device strives to reduce numbness, allowing users to regain sensation in their extremities. Improved Blood Circulation: A core benefit lies in the massager's ability to enhance blood circulation. The EMS technology stimulates blood flow to the feet and legs, ensuring a continuous supply of oxygen to nerve cells. Improved circulation contributes not only to pain relief but also to overall foot health. Muscle Strengthening: Beyond addressing neuropathic pain, the Nooro Foot Massager helps strengthen weakened muscles. The electric impulses penetrate deep into the tissues, promoting muscle stimulation. This additional benefit contributes to overall foot strength and may aid in preventing future discomfort. Convenience and Comfort: The cordless design, along with the straightforward operational steps, adds a layer of convenience to the user experience. The Nooro Foot Massager provides a hassle-free solution for those seeking comfort and relief. Users can enjoy the benefits of a personalized massage without the inconvenience of cords or complicated setup. How Does Nooro Foot Massager Work? (Nooro Foot Massager Reviews) The Nooro EMS Foot Massager operates on advanced EMS (Electrical Muscle Stimulation) technology, offering a multi-faceted approach to relieving discomfort. True to its name, using this device is as simple as placing your feet on it and letting it work its magic. Specifically, Nooro EMS Foot Massager works by increasing blood flow to your feet, the massager facilitates the delivery of much-needed oxygen to nerve cells. This groundbreaking approach opens the door to nerve repair and healing, reducing burning pain, tingling, and numbness. But here's the beauty of it – as long as your nerves are alive, there's hope for reversal. The National Institute of Health emphasizes the regenerative capacity of peripheral nerves when the underlying nerve cell remains intact. The Nooro Foot Massager becomes a tool for revitalization, offering relief and a chance to reclaim a life without constant foot pain. This innovative massager employs steady electric impulses that penetrate deep into your feet and legs, effectively targeting muscle tension. The result? Relaxation of tense muscles, which is essential for alleviating discomfort associated with neuropathic foot pain. What sets the Nooro Foot Massager apart is its versatility. With a variety of modes and an impressive array of speed settings, the device allows you to tailor your experience to address specific muscle groups. This flexibility ensures that you can find a satisfying combination, catering to the unique needs of whatever muscle group is causing you distress. In essence, the Nooro Foot Massager is designed to be user-friendly and customizable. Its cutting-edge EMS technology aims to enhance blood circulation, relieve muscle tension, and strengthen weakened muscles, all while providing a hassle-free experience. So, whether you're looking to unwind after a long day or target specific muscle groups causing discomfort, this device offers a personalized solution to meet your needs. Who Needs Nooro Foot Massager? Foot Pain and Discomfort: If your feet hurt or feel uncomfortable, the Nooro Foot Massager can give you relief and make you feel better. Plantar Fasciitis: If you have plantar fasciitis (pain in the bottom of your feet), using the massager can help ease the pain and make your feet more comfortable. Athletes and Runners: Athletes and runners can use the massager to relax their muscles and recover faster after exercising. Diabetes: If you have diabetes and your feet need extra care, the Nooro Foot Massager can be part of your routine to keep your feet comfortable. Swelling: If your feet are swollen, especially during pregnancy or due to certain health issues, the Nooro Foot Massager can help reduce the swelling. General Well-being: If you just want to feel better overall and more relaxed, using the Nooro Foot Massager can contribute to your well-being. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE AT A MASSIVE DISCOUNT Does Nooro EMS Foot Massager Really Work? Absolutely, the Nooro EMS Foot Massager has garnered positive reviews from satisfied customers, attesting to its effectiveness. Users express genuine satisfaction with the relief it provides, particularly in addressing knee-related concerns. Many have reported that it contributes to a positive sensation in their knees, offering comfort and support, especially before bedtime. Customers dealing with foot pains have found solace in the Nooro Foot Massager. The device seems to provide tangible relief, soothing discomfort associated with foot pains. The positive feedback highlights the impact of the massager in helping alleviate foot-related issues, making it a promising solution for those seeking relief from foot pain. One user shared their experience, noting the immediate positive effects after just one use. This firsthand account emphasizes the rapid and noticeable benefits users can expect, further reinforcing the idea that the Nooro EMS Foot Massager indeed works to bring comfort and relief. In essence, the testimonials from customers reflect a consensus that the Nooro EMS Foot Massager is not just a device but a reliable solution that genuinely addresses pain and discomfort, particularly in the knees. The positive feedback from users reinforces the notion that the Nooro Foot Massager is effective in delivering the relief it promises. How To Use Nooro Foot Massager? Using the Nooro EMS Foot Massager is delightfully straightforward, making it a hassle-free addition to your routine. First and foremost, you'll appreciate the absence of annoying cords – charging is a breeze with the included electricity plug and cable that come with your order. Once charged, the process is as simple as 1-2-3. For an optimal experience, the second step is optional but recommended – give your feet a quick wash and remove any excess skin. This preparatory step significantly enhances the effectiveness of the massage treatment. Now, you're ready to indulge in the soothing benefits of the Nooro Foot Massager. Just place your feet on the foot pad, select your preferred mode, and adjust the intensity level of the massage to your liking. It's a customizable experience tailored to meet your unique needs. From there, all that's left to do is sit back comfortably and let the massager work its magic. As it eases pain, relieves tingling, and liberates you from the challenges of neuropathy, you'll find a newfound sense of comfort and relief. The Nooro Foot Massager brings simplicity and effectiveness together, making it a user-friendly solution for those seeking relief from neuropathic foot pain. Price Of Nooro Foot Massager And Where To Buy Nooro Foot Massager can be gotten directly from the manufacturer’s official website at the following prices: Single Unit: Buy one Nooro Foot Massager for $99.95. Two Units: Buy two Nooro Foot Massagers for $94.95 each. Total cost: $189.90. Three Units: Buy three Nooro Foot Massagers for $89.95 each. Total cost: $269.85. Four Units: Buy four Nooro Foot Massagers for $87.95 each. Total cost: $351.80. Six Units: Buy six Nooro Foot Massagers for $84.95 each. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Nooro Foot Massager Reviews Consumer Reports And Customer Complaints The Nooro EMS Foot Massager has received overwhelmingly positive consumer reports, with an impressive 4.8-star rating and a noteworthy achievement of zero customer complaints. Thousands of individuals have experienced successful outcomes in reversing neuropathy with this device, highlighting its efficacy and customer satisfaction. Harry Keegan - “Superb relaxation, it's not bulky, so you can take it anywhere, cheaper than other massagers, does what it says. You'll love the "cupping mode". Many intensity options (up to 19). It's a great product with fast shipping! My wife loves it…” Debra Peyton - “Should have bought Nooro Foot Massager earlier, exactly what I needed for my neuropathy-pained-feet. Honestly, I can walk and move with just minimal pain. I've only used it for like 2 days and I have felt better than I have in the past 2 years!!!” Clara Milton - “I absolutely love my Nooro EMS Foot Massager massager, had to get one for my daughter today since she wont stop using mine!” Final Verdict On Nooro EMS Foot Massager Reviews The overwhelming positive reviews and testimonials for the Nooro Foot Massager paint a compelling picture of its effectiveness and customer satisfaction. With a remarkable 4.8-star rating and zero customer complaints, it stands out as a reliable solution for those seeking relief from neuropathic foot pain. Customers like Harry Keegan commend the massager for its superb relaxation, portability, affordability, and diverse intensity options. The mention of the "cupping mode" adds to the device's appeal. Debra Peyton's experience reinforces the quick and tangible relief the Nooro Foot Massager provides, enabling her to walk with minimal pain after just two days of use. Clara Milton's enthusiasm and the decision to purchase an additional massager for her daughter further underscore the positive impact and effectiveness of the device. In the final verdict, the Nooro Foot Massager emerges as a standout product, praised for its user-friendly design, versatility, and ability to address neuropathy-induced foot pain. The absence of customer complaints reinforces its credibility, making it a promising choice for those in search of a reliable and effective solution to neuropathic pain. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely substitutes for sound medical or financial advice from a licensed healthcare provider or certified financial advisor. Make sure to consult with a professional physician or financial consultant before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary. These products are not intended to diagnose, treat, cure or prevent any disease and do not provide any kind of get-rich money scheme. Reviewer is not responsible for pricing inaccuracies. Check product sales page for final prices. Contact Details Review Zenith Alex +1 302-597-6768 Alexreview@gmail.com Company Website https://reviewzenith.com

January 22, 2024 09:33 AM Eastern Standard Time

Image

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

Kadimastem

Ness Ziona, Israel, January 22, 2024, Kadimastem (TASE: KDST) and iTolerance Inc. announced today that the companies held a preliminary meeting with the INTERACT committee of the U.S Food and Drug Administration (FDA) on January 19 th, 2024 regarding the preclinical and clinical development leading toward commercialization of iTOL-102, a potential cure for diabetes that does not require chronic immune system suppression. Before the meeting, the companies received a response document from the FDA noting important feedback about the current preclinical plans which the companies intend to use for the advancement of their potential joint collaboration development plans. With the feedback from the INTERACT meeting received, the companies are working on the design and commencement of a clinical study of iTOL-102 that is planned to be submitted to the FDA for an IND in the future. Dr. Anthony Japour, Chief Executive Officer of iTolerance, commented, “We are pleased with the continued progress of our research collaboration with Kadimastem. With the INTERACT meeting now complete and the feedback received from our discussions with FDA, we are evaluating next steps toward a potentially innovative cure for patients with Type 1 diabetes.” Kadimastem CEO Asaf Shiloni said, " Thanks to our scientific teams who presented the joint collaboration project in an impressive manner. I am convinced that the helpful meeting and the relevant feedback will contribute to the continued progress of our planned joint product development and hopefully provide a cure for those living with diabetes.” In May 2023, the companies announced their research collaboration agreement to co-develop and commercialize a breakthrough and innovative regenerative technology to cure diabetes without the need for chronic immunosuppression and received a grant in the aggregate amount of US$1.0 million from the Binational Israel-U.S. Industrial R&D (BIRD) Foundation. As part of the agreement, the companies are considering expanding their cooperation and advancing the development of iTOL-102. The joint project is based on Kadimastem’s diabetes product called IsletRx, which is comprised of clinical-grade clusters of human pancreatic islet like cells (ILCs). Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce and secrete dependently, the required amounts of insulin and glucagon, just like a healthy pancreas. iTolerance, headquartered in Miami, Florida, has developed an innovative platform technology (iTOL-100) intended to enable the transplantation of allogeneic cells without tissue matching and without the need for chronic treatments that suppress the immune system of the transplant recipient (immunosuppression). This platform technology was successfully demonstrated in preclinical experiments in large animals (non-human primates), where diabetes was cured by allogeneic transplantation, without the need for long-term immunosuppressive treatments. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About iTolerance, Inc. iTolerance is an early-stage privately-held regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic pancreatic islets and stem cells that have the potential to cure diseases. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under Kadimastem’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the company's activity, as well as developments in the general environment and external factors affecting the company's activity. The company's results and achievements in the future may differ materially from any presented herein and the company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the company's securities or an invitation to receive such offers. Investment in securities in general and in the company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook Contact Details Kadimastem Asaf Shiloni CEO s.bazak@kadimastem.com iTolerance Jenene Thomas Chief Executive Officer, JTC Team, LLC +1 833-475-8247 iTolerance@jtcir.com Susan Roberts +1 202-779-0929 sr@roberts-communications.com Company Website https://www.kadimastem.com/

January 22, 2024 07:33 AM Eastern Standard Time

Image